Aravive, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • ARAV
  • 1d-13.39%
  • 1w0.00%
  • 1m-66.86%
  • 1y-97.90%
ATH
  • ATH Price$204.00
  • ATH Date2014-06-13
  • % since ATH-99.98%
  • % to ATH508,628.18%
ATL
  • ATL Price$0.04
  • ATL Date2024-01-26
  • % from ATL0%
  • Last Low Price$0.0401
  • Last Low Date2024-01-26
  • % From Last Low0%
IPO
  • IPO Price$31.00
  • % Current ROI USD-99.87%
  • ATH Price$204.00
  • % ROI ATH 50,872,817.96%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="ARAV"]

Key Data [addtoany]

Current price $0.0401
Sector Healthcare
Industry Biotechnology
Today's High/Low $0.0401/$0.0401
Volume 0.00
Previous Close $0.0463
52 Week High/Low $2.46/$0.04
Market Cap 2,949,860.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.09
Annualized Dividend $0
$0.0401
[addtoany]

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers.
The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.
It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc.
to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity